Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|December 18, 2025

Inside Codexis: Transforming RNA Manufacturing

Britton Jimenez, SVP of Sales and Marketing at Codexis, explains how the ECO Synthesis® Manufacturing Platform overcomes the limitations in scalability and sustainability that currently challenge the RNA therapeutics industry.

Key Objectives

  • Understand why increased demand impacts the development and manufacturing of RNA therapeutics
  • Recognize how Codexis is leading innovation in the RNA therapeutics space
  • Learn how Codexis helps its customers adopt the ECO Synthesis® Manufacturing Platform seamlessly

The RNA therapeutics market is rapidly growing but is currently limited by the scalability and sustainability issues inherent in decades-old solid phase synthesis technologies. Britton Jimenez, SVP of Sales and Marketing at Codexis, addresses these limitations and introduces the novel ECO Synthesis® Manufacturing Platform, a fully aqueous system that allows for massive batch sizes, feasibly scaling up to 500 kgs. He also details how Codexis utilizes machine learning and AI, building on its CodeEvolver platform history, to optimize manufacturing strategies and proactively engage with the FDA to ensure that customers have a clear regulatory pathway for bringing their therapeutics to market.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.